Opinion

Video

Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

Author(s):

Trinity Bivalacqua, MD, PhD,Mark D. Tyson, MD, MPH

Key opinion leaders examine the comparative safety profiles and response durations of combination therapy versus monotherapy in the treatment of BCG-unresponsive carcinoma in situ with or without papillary disease.

Current Time 0:00
Duration 1:14
Loaded: 0%
Stream Type LIVE
Remaining Time 1:14
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following questions:

    • Did safety outcomes with combination therapy vary from those observed with monotherapy cretostimogene or pembrolizumab?
    • Can you please talk about the duration of response and how this compares to other agents that have been tested in BCG UR CIS +/- papillary disease?

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    DNA helix | Image Credit: © Radomir Jovanovic - stock.adobe.com
    Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
    Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
    TMT for bladder cancer: Balancing cost and quality of life
    Anne Schuckman, MD, outlines current challenges in NMIBC care
    Anne Schuckman, MD, outlines current challenges in NMIBC care
    Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
    Investigators compare trimodal therapy vs cystectomy in MIBC
    Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
    Investigators assess ctDNA’s role in NMIBC
    Urology Times Mitomycin RX Review Square Thumb
    RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
    Urology Times Mitomycin RX Review Square Thumb
    RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
    Urology Times Mitomycin RX Review Square Thumb
    RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
    Urology Times Mitomycin RX Review Square Thumb
    RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
    Urology Times Mitomycin RX Review Square Thumb
    RX Review: Redefining treatment for LG-IR-NMIBC
    Related Content
    Data supports combination intravesical chemotherapy for high-risk NMIBC
    July 10th 2025

    Data supports combination intravesical chemotherapy for high-risk NMIBC

    Hannah Clarke
    “This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.
    medical depiction of bladder cancer
    May 31st 2023

    Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

    Urology Times staff
    In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
    Human urinary system | Image Credit: © magicmine - stock.adobe.com
    July 8th 2025

    Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC

    Benjamin P. Saylor Hannah Clarke
    Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.
    Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
    December 7th 2021

    Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

    Urology Times staff
    “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
    Regulatory recap: FDA approvals in urology from the first half of 2025
    July 4th 2025

    Regulatory recap: FDA approvals in urology from the first half of 2025

    Hannah Clarke
    Take a look through all the regulatory milestones in urology from the first half of the 2025.
    Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
    July 4th 2025

    Top 10 Urology Times videos from the first half of 2025

    Urology Times staff
    Catch up on exclusive videos you may have missed from the first half of the year.
    © 2025 MJH Life Sciences

    All rights reserved.